Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

Considering the fundamental role of protein kinases in the mechanism of protein
phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has …

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …

Opinion statement Inflammatory myofibroblastic tumor (IMT), characterized by intermediate
malignancy and a propensity for recurrence, has presented a formidable clinical challenge …

A narrative review of methods for the identification of ALK fusions in patients with non-small
cell lung carcinoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …

Acquired drug resistance remains a major problem across oncogene-addicted cancers.
Elucidation of mechanisms of resistance can inform rational treatment strategies for patients …

Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in
various cellular processes, including cell migration, morphological differentiation, cell …

Simple Summary Oncofusions, or cancer-associated fusion mutations, are driving forces in
cancer development. Advanced sequencing technologies have revolutionized their …